Clinical development of targeted and immune based anti-cancer therapies
NA Seebacher, AE Stacy, GM Porter… - Journal of Experimental & …, 2019 - Springer
Cancer is currently the second leading cause of death globally and is expected to be
responsible for approximately 9.6 million deaths in 2018. With an unprecedented …
responsible for approximately 9.6 million deaths in 2018. With an unprecedented …
EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer
E Tulchinsky, O Demidov, M Kriajevska… - … et Biophysica Acta (BBA …, 2019 - Elsevier
Epithelial mesenchymal transition (EMT) is a reversible developmental genetic programme
of transdifferentiation of polarised epithelial cells to mesenchymal cells. In cancer, EMT is an …
of transdifferentiation of polarised epithelial cells to mesenchymal cells. In cancer, EMT is an …
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm …
Y Shi, X Hu, S Zhang, D Lv, L Wu, Q Yu… - The Lancet …, 2021 - thelancet.com
Background Furmonertinib (AST2818) is a third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI) targeting both sensitising EGFR and EGFR Thr790Met …
(EGFR) tyrosine kinase inhibitor (TKI) targeting both sensitising EGFR and EGFR Thr790Met …
Design, synthesis and anticancer evaluation of thieno [2, 3-d] pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers
Deregulation of many kinases is directly linked to cancer development and the tyrosine
kinase family is one of the most important targets in current cancer therapy regimens. In this …
kinase family is one of the most important targets in current cancer therapy regimens. In this …
Development of EGFR TKIs and options to manage resistance of third-generation EGFR TKI osimertinib: conventional ways and immune checkpoint inhibitors
L Wu, L Ke, Z Zhang, J Yu, X Meng - Frontiers in Oncology, 2020 - frontiersin.org
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have been first-line
therapy in the treatment of non-small cell lung cancer (NSCLC) harboring EGFR sensitive …
therapy in the treatment of non-small cell lung cancer (NSCLC) harboring EGFR sensitive …
Mutant‐selective allosteric EGFR degraders are effective against a broad range of drug‐resistant mutations
Targeting epidermal growth factor receptor (EGFR) through an allosteric mechanism
provides a potential therapeutic strategy to overcome drug‐resistant EGFR mutations that …
provides a potential therapeutic strategy to overcome drug‐resistant EGFR mutations that …
Start selective and rigidify: the discovery path toward a next generation of EGFR tyrosine kinase inhibitors
H Engelhardt, D Böse, M Petronczki… - Journal of medicinal …, 2019 - ACS Publications
The epidermal growth factor receptor (EGFR), when carrying an activating mutation like
del19 or L858R, acts as an oncogenic driver in a subset of lung tumors. While tumor …
del19 or L858R, acts as an oncogenic driver in a subset of lung tumors. While tumor …
mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 are druggable candidates for N-(2, 4-difluorophenyl)-2′, 4′-difluoro-4-hydroxybiphenyl-3-carboxamide (NSC765598) …
Background The application of computational and multi-omics approaches has aided our
understanding of carcinogenesis and the development of therapeutic strategies …
understanding of carcinogenesis and the development of therapeutic strategies …
[HTML][HTML] Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/β-Catenin activity and cancer stemness
R Yan, X Fan, Z Xiao, H Liu, X Huang, J Liu, S Zhang… - Cancer letters, 2022 - Elsevier
Lung adenocarcinoma is the most common form of lung cancer, accounting for 60% of non-
small cell lung cancer (NSCLC) cases in Asian patients. Importantly, nearly half of these …
small cell lung cancer (NSCLC) cases in Asian patients. Importantly, nearly half of these …
Acquired resistance mechanisms to osimertinib: the constant battle
Z Zalaquett, MCR Hachem, Y Kassis, S Hachem… - Cancer Treatment …, 2023 - Elsevier
Lung cancer is the leading cause of cancer-related mortality worldwide. Detectable driver
mutations have now changed the course of lung cancer treatment with the emergence of …
mutations have now changed the course of lung cancer treatment with the emergence of …